Form 4: UTHR COO Sells Shares After Option Exercise

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and sold 22,500 common shares on September 29, 2025, under a Rule 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), executed a series of transactions on September 29, 2025.
• These transactions involved the exercise of stock options and the subsequent sale of common stock, all conducted under a pre-arranged Rule 10b5-1 trading plan established on June 3, 2025.
• From a trust where Benkowitz is a beneficiary and co-trustee, 14,625 stock options were exercised at a price of $135.42 per share.
• Concurrently, 14,625 shares of common stock from this trust were sold at weighted average prices ranging from $416.596 to $430.7482.
• From a second trust, where family members are beneficiaries and Benkowitz has sole investment/voting power, 7,875 stock options were exercised at a price of $146.03 per share.
• Subsequently, 7,875 shares of common stock from this second trust were sold at weighted average prices ranging from $416.596 to $430.7477.
• In total, 22,500 stock options were exercised and 22,500 shares of common stock were sold.
• Following these transactions, the beneficial ownership in both trusts for the shares resulting from these exercises is 0.00.
• Benkowitz retains indirect beneficial ownership of 114,375 stock options through the first trust and 25,375 stock options through the second trust.
• Additionally, Benkowitz directly holds 2,648 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports a pre-planned insider transaction (exercise of options and sale of shares) under a Rule 10b5-1 plan, which is a routine event and does not inherently indicate positive or negative company performance or outlook. The transactions are a personal financial event for the executive.

Positives

• The exercise of stock options indicates that the options were significantly in-the-money, reflecting a profitable transaction for the reporting person.
• The transactions were executed under a Rule 10b5-1 trading plan, which suggests the sales were pre-planned and not based on immediate, non-public information, mitigating concerns about opportunistic insider selling.

Negatives

• The sale of 22,500 shares by a key executive reduces their direct equity stake in the company, which some investors might view with caution, despite the pre-planned nature of the transaction.

Risks

• No specific company-related operational or financial risks were disclosed in this Form 4 filing, as it primarily reports insider trading activity.

Future Outlook

This Form 4 filing pertains to an insider's personal trading activity and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction for an executive in the biotechnology/pharmaceutical industry. Such transactions are common for executives managing their personal finances and equity compensation, and do not typically reflect broader industry trends or competitive positioning.

Related Party Transactions

• The reported transactions involve an executive (Michael Benkowitz) of United Therapeutics Corp, making them related-party dealings in the context of insider reporting. However, they are standard compensation-related transactions executed under a pre-arranged plan, not unusual related-party transactions.

Stakeholder Impact

• Shareholders: May note the reduction in the executive's direct equity holdings, though the pre-planned nature mitigates concerns about opportunistic selling. The executive still retains significant option holdings and some direct shares.
• Employees: No direct impact on employees or operations is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Key Dates

Recommendation

This Form 4 reports a pre-scheduled exercise of stock options and subsequent sale of shares by a key executive under a Rule 10b5-1 trading plan. Such transactions are routine for executive compensation and do not typically reflect a change in the company's fundamental outlook or performance. Therefore, it does not provide new information that would alter an existing investment thesis for United Therapeutics Corp, warranting a 'hold' recommendation.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Executive Compensation, Rule 10b5-1, Michael Benkowitz, Biotechnology, Pharmaceuticals